ABSTRACT
The acceptance of paternally-derived alloantigens during pregnancy and escape from host immunosurveillance by cancer are based on similar immunological mechanisms. Among them both natural and peripherally-induced T CD4+CD25+Foxp3+ and Tr1 regulatory cells (Tregs) play important role. Interactions of Tregs with other immunocytes including dendritic cells, mechanisms of Tregs recruitment and their suppressive properties in cancer and pregnancy have been presented in this paper. Despite the fact that mechanisms of Treg regulation are still in progress, there is a hope for use of Tregs-related immunotherapy in clinical practice, and the first attempts of such management have already been described. However, more information about the function of Tregs cells is needed to provide safe treatment devoid of potential side-effects. Resolving the secrets of Tregs cells will probably offer new options of cancer treatment and will help to improve the management of pregnancy failure.
INTRODUCTION
During normal pregnancy maternal immune system tolerates the fetal tissues despite of the presence of paternal alloantigens on the surface of trophoblast. It was Medawar, who first proposed that growing fetus should be viewed as allotransplant (1), and many investigations considering both physiological and pathological course of pregnancy seem to support that hypothesis (reviewed in 2). Since that time the possible mechanisms of fetal allograft escape from maternal immunosurveillance have been extensively discussed. After years of considering pregnancy as a state of systemic maternal immune suppression, the time has come to define it as a precisely regulated state of tolerance dependent on many cooperating mechanisms, of preferentially local (maternal-fetal interface) area of action. Based on both murine and human studies there were several mechanisms proposed to contribute to that tolerance: inactivation of NK cells through HLA-G expressed on trophoblast (3), depletion of tryptophan by indoleamine 2,3-dioxygenase (IDO)-dependent mechanism (4, 5, 6) , heme oxygenase (HO)-1 expression on decidual and placental tissues (7, 8) , increased trophoblast-induced apoptosis of maternal effector cells (9) , the presence of asymmetric blockingantibodies (10) , and an adequate Th1/Th2 cytokine crosstalk (11, 12, 13) . Recent data are also strongly suggestive, that placenta-derived exosome particles present in the maternal circulation could regulate immune activation by mediating activation-induced apoptosis of maternal reactive lymphocytes (14) .
Cancer developing in the host environment originates from "self" tissues, however, during development it acquires new genetic and phenotypic characteristics due to mutations. Genetic instability can produce immunogenic antigens either by the overexpression of cell proteins or by the expression of mutated proteins (15) . These antigens (called tumor-associated antigens -TAA) provide a target for effector immune defense mechanisms of the host. Despite of this fact, in most situations cancer is able to escape from the host immunosurveillance and to grow and metastatize succesfully. There are several mechanisms that could be responsible for this phenomenon: total or selective loss of HLA class I molecules (16) , surface expression of HLA-G antigen (17) , tumor-mediated shedding of MHC class I related molecules (18) , shift towards Th2-type cytokine activity produced by host immune cells or tumor itself (19) , and up-regulation of the surface Fas ligand on cancer cells leading to enhanced apoptosis of effector immune cells (20) . It was also shown that depletion of tryptophan by tumor-derived IDO could make tumor's cells resistant to immune attack (21) . IDO-high expression was associated with a significant reduction of tumor T CD3+ infiltrating cells and correlated with the frequency of liver metastases and decreased patient survival (22) . Heme oxygenase-1 protects tumor cells against hypoxic stress, showing antiapoptotic and anti-inflammatory properties (23, 24) , and controls cancer cells proliferation and tumor angiogenesis, which was indicated by studies performed on animal and human tumors (25, 26, 27) . Both tumor cells and tumorassociated macrophages indicated HO-1 expression (28, 29, 30, 31) . Increased HO-1 expression in tumor microenvironment could account for its progressive growth. Knockdown of HO-1 expression led to cancer growth inhibition and made the tumor cells more sensitive to chemo-and radiotherapy (32) . The interplay between IDO and HO-1 produced by immunocytes or tumor itself could either stimulate or inhibit the tumor growth (33) . Tumor-derived exosome-like particles released from cancer cells membranes are also capable of suppression T cell signaling in anti-tumor effector lymphocytes leading to their apoptosis (34) .
An interesting issue is that both pregnancy and cancer share similar mechanisms of escape from host immunosurveillance (35) . However, none of the above mentioned mechanisms could profoundly explain the observed down-regulation of maternal alloreactive immunocompetent cells or "host consent" for cancer progression. The acceptance of paternally-derived tumor cells by pregnant animals (36) suggests the possibility of systemic regulation involvement during pregnancy, which could be due to T regulatory cells (Tregs). Although tumor  cells have antigens altered by mutation, antigenic similarity  to self-somatic cells engages also systemic regulation of the  peripheral tolerance maintained by Tregs. Treg cells belong  to naturally occurring T CD4+CD25+  high cells, peripherally  induced T CD4+CD25+ high population, and Tr1 IL-10+ cells. They all constitute an interesting mechanism of immunological escape which has been extensively studied in recent years both in pregnancy and cancer. Understanding of immunological phenomena which evolved in mammals in order to recognize alloantigens or changed self tissues might help to create new techniques of cancer treatment and to improve management of pregnancy complications.
THE ROLE OF T CD4+CD25+ HIGH FOXP3+ CELLS IN CANCER PROGRESSION

Mechanisms of Tregs recruitment and function in cancer
Development of cancer and poor prognosis in tumor-bearing patients is accompanied by accumulation of natural Treg cells in peripheral blood, draining lymph nodes and tumor itself (37, 38, 39, 40, 41, 42, 43, 44, 45, 46) . Regulatory T Foxp3+ cells seem to be dominant bad prognostic factor even if high expression of IFN-gamma was identified (47). Regulatory T cells capable of abrogating anti-tumor reactivity are also primed peripherally together with effector T cells in the same lymphatic nodes during tumor progression. This Treg population indicates high expression of CD62L neccessary for Treg recruitment into lymphoid nodes, as well as very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1 (LFA-1) which both play role in trafficking T cells into inflammatory sites (48). Human CD4+CD25+ Tregs also preferentially move towards and accumulate in tumors. These are probably chemokine (C-C motif) ligand 22 (CCL22) or IL-16 produced by tumor cells and tumorinfiltrating macrophages which mediate trafficking of Tregs into the tumor tissue, ascites and pleural effusions (37, 49 
Peripheral Tregs interactions in cancer
Circulating in blood Treg cells belong to thymically-derived natural T CD4+CD25+ high population, but those seen inside lymphatic nodes and tumor tissues result from local proliferation dependent on TGF-beta signalling (52, 61). Increased levels of cancer-derived TGF-beta or alternatively of TGF-beta cancer-induced secretion in tumor environment were found to augment tumor growth and to enhance escape from host immunosurveillance (62, 63, 64, 65) . The presence of endometrial bleeding associated factor TGFB4 (ebaf), a member of TGF-beta superfamily, was confirmed in adenocarcinomas with mucinous differentiation (66) . Because TGF-beta promotes Treg cell generation, it is suspected that tumor itself is capable of stimulating Treg cell activity. This possibility was confirmed by the observation that Foxp3-expressing Treg cells were increased in patients with active cancer and decreased during remission (67, 68) . Another possibility concerns promotion of Tregs by TGF-beta produced by a subset of pro-tolerogenic iDCs present in tumor or in draining lymph nodes (54). It was found that progressive tumors contained increased numbers of CD4-8-tumor-infiltrating dendritic cells (TIDCs), which secreted a marked levels of TGF-beta, thus leading to immune suppression and tumor progression. In contrary, regressive tumors contained CD4+8+ and CD4+8-TIDCs which were able to express high levels of IFN-gamma and IL-6, and could stimulate Th1-type cytokine responses and effective cytotoxic lymphocyte (CTL) anti-tumor responses (69) . Dendritic cells are able to present MHC class I-restricted antigens captured from apoptotic tumor cells and initiate cytotoxic T CD8+ antitumor responses. Therefore an impaired TIDCs function could not only stimulate Treg activity but also could be at least in part responsible for defective T CD8+ cell function. Interleukin-10 is probably responsible for augmentation of these effects, because in IL-10-knockout mice restoration of TIDCs and T CD8+ anti-tumor functions was successfuly obtained (70) .
An additional mechanism of Treg regulation by DCs engages CD200/CD200-receptor pathway. Molecule CD200 is a type Ia membrane protein related to CD80/CD86 family of costimulatory molecules, exerting its suppressive action through specific CD200 receptor (CD200R). Both CD200 and CD200R is expressed on monocyte-derived dendritic cells. Stimulation of CD200R on DCs created tumor-promoting milieu by shifting cytokine secretion into Th2 profile and by induction of Treg cells. Blocking CD200/CD200R pathway using monoclonal anti-CD200 antibodies augmented Th1 responses directed against leukemic cells. Moreover, tumor itself could contribute to regulation of host defense by upregulation of CD200 molecules on leukemic cells (71, 72) . Clinical observations confirm the importance of CD200 molecule for tumor development as in multiple myeloma patients high CD200 expression on cancer cells was found to be an unfavorable prognostic factor for progression-free survival (73) .
Induced Tregs could in turn modify function of DCs in tumor environment. The CTLA-4-dependent TregDCs interactions could effectively down-regulate antitumor immunity in IDO-dependent manner. Blocking of CTLA-4-dependent pathway resulted in reduced Treg activity (38) . The presence of IDO-expressing DCs was confirmed in tumor-draining lymph nodes from patients with melanoma, breast, colon, lung and pancreatic cancers (74) , while the number of IDO-positive cells infiltrating peri-tumoral tissues was found to correlate with poor patient survival in non-small cell lung cancer (75) . As confirmation of IDO importance for anti-cancer immunity low serum median tryptophan concentrations were found in melanoma patients who subsequently died because of tumor progression (76) . Apart from DCs, the cancer cells themselves could express IDO which were capable of modulating Treg-DC-effector cells interactions. In endometrial cancer high IDO expression in tumor cells was found to correlate with overall and progression-free survival (77) . Moreover, prostaglandin-E2 in the tumor environment might influence IDO expression in peritumoral DCs (78) (Figure 1 ).
THE ROLE OF T CD4+CD25+ HIGH FOXP3+ CELLS IN PREGNANCY
Distribution of Tregs during pregnancy
Regulatory T cells are necessary component of maternal immune tolerance of paternal alloantigens present on trophoblast. Syngenic pregnancies in mice proceeded normally in Treg-depleted animals, but ended unfavorably in allogenically mated parents, suggesting not only that Treg cells were indispensable component of pregnancy, but also that they did not suppress female reaction directed towards male minor histocompatibility antigens (79) . In fact we are still not sure what kind of antigen is recognized by Tregs in pregnancy. They might recognize maternal self antigens on semi-allogeneic trophoblast and then suppress alloreactive effector cells by mechanism of "bystander suppression". As isolated CD4+CD25+
high Treg cells expressing Foxp3 antigen were capable of suppression of effectory responses to allogeneic dendritic cells (80) , the possibility of direct alloantigen recognition by Tregs could not be excluded (79, 81) . This supposition is confirmed by observation that transferring of CD4+CD25+ Treg cells into abortion-prone mice could prevent abortion but only when Treg cells originated from normal pregnant mice, suggesting that exclusively Treg cells exposed previously to paternal alloantigens could exert regulatory activity (82, 83) . The treatment of female mice with an anti-CD25 antibody before mating resulted in depletion of Tregs and fetus rejection (84, 85) .
In pregnant mice the proportion of CD4+CD25+ Treg cells increased significantly in the spleen, uterinedraining lymph nodes and peripheral blood, starting from the early post-implantation period. Correspondingly, in human pregnancy CD4+CD25+
high Treg cells contributed to 8% of peripheral blood and to 20% of decidual CD4+ T cells respectively (86, 87). In pregnant women an increase in circulating Treg cells during early pregnancy, reaching the highest level in the second trimester and then declining post partum was observed. The percentage of T CD4+CD25+ high cells was increased in peripheral blood of patients having normal pregnancy compared to women with spontaneous abortion and non-pregnant subjects (88).
Moreover, the percentage of Tregs as well as the expression of CTLA-4 on their surface was higher inside decidua than in blood, but this was not seen in the case of spontaneous abortion (88, 89, 90) . The percentage of T CD4+CD25+ regulatory cells decreases inside decidua of pregnant women with spontaneous vaginal delivery compared to patients having elective caesarean section without contractions (91) suggesting their possible role not only in sustaining the pregnancy but also in the regulation of labour.
Treg cells could be preferentially recruited or alternatively induced locally inside maternal-fetal interface (82) . Preferential recruitment of Treg cells into maternalfetal interface may depend on expression of chemokine receptor CCR4 on their surface, as it was confirmed that the chemotactic factor for CCR4, thymus and activationregulated chemokine (TARC) is expressed on trophoblast, endometrial cells and uterine epithelial cells (92) . Another candidate for regulator of Tregs recruitment into maternalfetal interface was chemokine receptor CCR5. Regulatory T CCR5+ cells preferentially accumulated inside gravid uterus where they were enhanced by contact with paternally-derived alloantigens (93) . The most important sites of Treg-mediated suppression in pregnancy are probably both uterine-draining lymph nodes and decidua (79, 85).
Regulation of Tregs function in pregnancy
Expansion of Tregs during pregnancy probably depends on hormonal changes, alterations in the expression of co-stimulatory molecules or alterations of DC function (79) . It was shown that estradiol was able to enhance the proliferation of T CD4+CD25+ cells in response to CD3/CD28 activation in vitro, which was dependent on the presence of estrogen receptor-alpha (ER-alpha) on Treg cells surface (94) . Estradiol together with TCR stimulation amplified Foxp3 expression on T CD4+CD25-cells, converting them into Treg phenotype. Pregnancy causes similar level of Foxp3 expression as in vitro treatment of T CD4+CD25-cells with estradiol, suggesting that high estrogen levels during pregnancy may help to maintain fetal tolerance (95) . Moreover, there is evidence that 17-betaestradiol could directly induce expression of IDO on monocyte-derived DCs, thus limiting T cell proliferation (96) . It was also found that both estradiol and progesterone could influence cytokine production by DCs, converting them into Th2 cytokine profile represented by secretion of IL-10, and thus influencing pro-suppressor interactions with Tregs (97, 98, 99) . Suppressor T CD8+ lymphocytes possessing progesterone receptor and secreting IL-10 and progesterone-induced blocking factor (PIBF), which low urine concentration is connected to early pregnancy failure (100), were shown to be another population of hormonallydependent modulatory cells (101) , however , their role in interactions with CD4+CD25+
high Tregs needs to be elucidated.
The importance of CD80/CD28 and CD80/CTLA-4 interactions on T cell suppressor activity was confirmed in animal studies performed on abortion prone CBA/J x DBA/2 mouse matings. Compared to normal pregnant mice abortion-prone CBA/J females showed increased frequency of IFNγ-producing antipaternal T cells in decidua and diminished number of T CD4+/CD25+ as well as IL-10+ Treg cells in thymus (102) . Maternal tolerance for the paternal alloantigens could be successfully achieved either by administration of anti-CD86 monoclonal antibodies to CBA/J females or the adoptive transfer of Tregs from normal pregnant mice (102, 103, 104, 105) . This management resulted in up-regulated expression of IL-10 and CTLA-4, and down-regulated expression of IFN-gamma, IL-2 and CD28 on recipient's T cells, confirming that CTLA-4/CD80 interactions in the absence of CD86 expression could preferentially restrict T cell activation and Th1 cytokine secretion (104, 105) . Therefore, the level of expression of co-stimulatory molecules, especially CTLA-4, could influence the maternal immune response towards the fetus (103).
Tregs -DCs interactions in pregnancy
Alterations of DCs function in the course of pregnancy are also considered as a strong candidate for regulator of Tregs activity. Morphometric analysis performed during mouse pregnancy confirmed the presence of DCs inside decidua and indicated that the average density of decidual DCs at early pregnancy was significantly higher compared to mid-pregnancy and late gestation or to non-pregnant state. At early pregnancy DCs were concentrated adjacent to the luminal epithelium, whereas later on, were randomly distributed in the stroma (106) . Differences of DCs localization could reflect their functional importance for pregnancy maintenance. Comparison between immature vs. mature DCs showed that in mice, the number of mature DCs found inside decidua at the time of implantation is decreased, however, in pregnancies in abortion-prone matings exposed to stress an increase of mature DCs was observed. Immature DCs through decreased intercellular adhesion molecule-1 (ICAM-1)/LFA-1 interactions were capable of suppressing effector T cells, and by increasing IDO and IL-10 secretion might in turn favour Treg cells (107) . During maturation DCs strongly up-regulated co-stimulatory molecules CD80 and ICAM-1, which by interaction with their ligands CD28 and LFA-1 on T cells provided crucial signal for T cell activation. Changed ICAM-1/LFA-1 cross talk was responsible for increased recruitment of pro-inflammatory cells to implantation site and subsequent Th1 polarization and pregnancy failure (107) . Recent data demonstrated that IDO expression on both peripheral blood and decidual DCs after treatment with CTLA-4/Fc fusion protein or IFNgamma is up-regulated in normal pregnancy, whereas decreased in spontaneous abortion (108) . Defective CD86 expression on DCs and inefficient IFN-gamma secretion by DCs activated by CTLA-4/Fc protein were observed and could account for pregnancy failure (108) . Immature DC cells have been described inside decidua during normal early pregnancy in humans (109) . Immature IL-10-producing DCs are capable of suppressing T cells by IDO expression, Treg up-regulation and induction of Th2 cytokines production in the mechanism of "bystander suppression" (107, 110) . Autoregulation of DCs by IDO stimulates their regulatory function by enhancement of secretion of IL-10 and TGF-beta (4). Decreased levels of IDO were observed in mice with increased fetal losses (111) and administration of IDO inhibitor (1-methyltryptophan) to pregnant mice provoked abortion (4). In humans expression of IDO was found to be 10-fold higher in DCs of pregnants when compared to controls (112) . The presence of IDO expression in human invasive extravillous trophoblast suggested that it could participate in protection of the fetus by down-regulating local maternal T responses (113) . However, the precise role of IDO during pregnancy should be clarified as allogenically mated IDO-knockout mice did not show a decrease in the size of pups (114) . Similarly, like in cancer, CD200/CD200R pathway could influence Treg function inside maternal-fetal interface. Decidual DCs were shown to bear CD200R molecules, and could mediate Treg function in IDO-dependent mechanism, thus preventing abortions (115, 116) . They were also capable of modulating function of other T cell populations as it was shown that male lymphocyte immunization of aborting mice stimulated female γδT CD4 cells for secretion of Th2 cytokines through the mediation of protolerance molecule CD200. Its role was confirmed in investigations which showed that loss of CD200 from stored overnight lymphocytes resulted in ineffective immunotherapy (117).
THE ROLE OF Tr1 CELLS IN PREGNANCY AND CANCER
Tr1 cells in pregnancy
The data concerning the role of type 1 regulatory T cells (Tr1) in the maintenance of pregnancy are scarce, however, such connections have been suggested by studies performed both on animals and humans. Compared to abortion-prone mice, normal pregnant mice presented with increased populations of IL-10+ Treg cells capable of inhibiting proliferation and IFNγ secretion of effector cells (102) . In normal pregnant women decidual gamma/delta T cells expressed IL-10 and TGF-beta, and thus had the potential to induce the differentiation of Th0 TCRαβ+ cells into regulatory/suppressor Tr1 and Th3 cells (118) . This mechanism did not operate inside maternal-fetal interface of recurrent aborters, due to improper activation of cytotoxic NK cells that could unfavourably influence gamma/delta T cell function (119) . Contradictory data indicating that lowered levels of IL-10 were reported in peripheral blood lymphocytes of recurrent abortion patients (120), while in IL-4/IL-10 knockout mice pregnancy resulted in healthy normal pups (121) , rise the questions concerning the true role of IL-10 in pregnancy success as well as the role of IL-10-producing Tr1 cells. The function of Tr1 cells in pregnancy awaits precise elucidation.
Tr1 cells in cancer
The role of Tr1-mediated activity for progression of cancer has been proved by many studies. Regulatory Tr1 cells can be isolated from tumor-infiltrating lymphocytes in the B16 melanoma model. Transfer of this cells facilitated tumor growth in syngenic mice and injection of IL-10 in the tumor site promoted tumor progression (reviewed in 122). Subcutaneous inoculation of melanoma cells in murine model of anti-cancer immunity resulted in accumulation of large number of CD4+ Th3 and CD4+ Tr1 regulatory cells producing TGF-beta and IL-10 and thus collapsing local anti-tumor response represented by cytotoxic T CD8+ and NK cells (123) . It was suggested that both DCs and gamma/delta T cells could be involved in recruitment and proliferation of Tr1 and Th3 Tregs. Removal of these Treg cell populations from tumor environment might be conceivable way to augment antitumor defense (123) . The tumor cells themselves are capable of directing host immunity into tolerogenic state. It was shown that myeloma cell lysates affected DCs function by forcing them to production of large amounts of IL-10, but no IL-12. Interleukin-10 inhibits the stimulatory capacity of DCs through down regulation of MHC class II antigens and the costimulatory CD80/CD86 molecules, thus inhibiting DC maturation and polarizing DCs to tolerogenic rather than stimulatory activity (124) . Such stimulated DCs generated further IL-10-producing T cells of Tr1 profile (125) . Murine studies proved that immature TGF-beta-secreting CD4-CD8-immature DCs promoted expansion of Tr1 regulatory cells which in turn, when transferred into other mice, could enhance tumor growth. Using of IL-10 -/-T cells or depleting Tr1 cell population restored anti-tumor immunity (126) . It has been also revealed that exposure to an adenoviral vector expressing a prostate specific antigen (PSA) (127) or COX-2-overexpressing tumors induce a Tr1 response, which is mediated by tumor-exposed, IL-10-enhanced DCs (128) . Interleukin-10 secretion by both malignant and reactive cells is thought to be important in the pathogenesis of Hodgkin lymphoma (HL) (129) . HL-infiltrating lymphocytes contained large populations of IL-10-secreting CD4+ Tr1, CD8+ Tr1 and CD4+CD25+ regulatory T cells which provided a profoundly immunosuppressive environment and were highly responsible for the ineffective immune clearance of HL cells (130) . The importance of Tr1-dependent regulation was supported by observation that neutralization of IL-10 ameliorated HL progression (131) . Recently bladder carcinoma was found to be a Tr1 dominated tumor, as was shown by the presence of TGF-beta and IL-10 mRNA copies (132) . Tr1-derived interleukin-10 could play an important role in the immunosuppression of anti-cancer immunity (133) . Elevated levels of IL-10 correlated with different types of tumors as well as with an unfavorable prognosis in patients (134) . However, it seems that situation differs depending on tumor type, and in some hematological malignancies like chronic lymphatic leukemia (CLL), expression of IL-10 has been associated with a favorable outcome (135) . Similarly, studies on murine glioma model indicated that IL-10 may have protective role against tumor by enhancing CTL or NK cell function (reviewed in 122). Furthermore, transgenic mice constitutively expressing high levels of IL-10 are also not impaired in their ability to clear allogenic tumors (136) . Therefore, the precise role of Tr1 cells and IL-10 in creating pro-tumoral environment needs further investigations (Figure 1. ).
6.
TREG-RELATED IMMUNOTHERAPY IN PREGNANCY AND CANCER
Treg-related immunotherapy in pregnancy
The role of Treg cells in maintaining pregnancy and promoting the tumor growth investigated both in mice and humans gives rise to the question concerning the possibilities of manipulating Treg function for treatment of pregnancy failures and in anti-cancer therapy.
The attempts of immunotherapy influencing Tregs during pregnancy concentrated either on transferring Tregs into abortion-prone animals or on modulating and potentiation of the function of existing Tregs by DCs. The adoptive transfer of Treg cells from normal pregnant mice into abortion-prone females was proved to significantly diminish the abortion rate (82) by expanding both the peripheral and thymic Treg populations (83) . The precise mechanism of such treatment is still obscure, however, it does not seem that it is based simply on inhibition of maternal cytotoxic and Th1 responses, as decidual levels of IFN-gamma and TNF-alpha were not diminished after therapy. Instead of inhibition, the creation of immunotolerant environment represented by up-regulation of leukemia inhibitory factor, TGF-beta and HO-1 at the fetalmaternal interface was confirmed (83) . Several reports suggested that both murine and human CD4+CD25+Foxp3+ Tregs could be multiplied in vitro from CD4+CD25-T cells cultured in the presence of IL-2 (137, 138) or by retroviral transduction of CD4+CD25-T cells with Foxp3 (139, 140) . Obtained during such in vitro manipulation Tregs could be successfully used in vivo. Alternative way of Treg-mediated immunotherapy investigated in abortion prone CBA/J x DBA/2 matings used transfer of anti-CD80 or anti-CD86-treated paternal T cells from DBA/2 males into CBA/J females. Modified paternal T cells had suppressive properties directed towards maternal effector T lymphocytes suggesting improved Treg activity (103) . Therapy employing DCs also proved to diminish the pregnancy failure rate in animal CBA/J x DBA/2 abortion model. It was shown that syngeneic DC therapy resulted in an increase in T CD8 suppressors and gammadelta T cells as well as in up-regulation of TGF-beta and PIBF expression at the maternal-fetal interface (141) . However, another contradictory results indicated that IDO and IL-10 co-expressing DCs were not capable of suppressing allogeneic T cell responses (142) . Therefore, DC-mediated immune modulation in pregnancy is still the matter of future, similarly like pharmacologically targeted therapies to modify metabolic pathways of Foxp3 expression (143) . The connection between therapeutic use of intravenous immunoglobulins (IVIG) or paternal lymphocyte immunotherapy in women suffering from recurrent spontaneous abortions and Treg cells function also awaits for solution.
Treg-related immunotherapy in cancer
Modifying the Treg number and function for establishing regression of cancer has been studied more extensively than in pregnancy. Depletion of CD4+CD25+ Tregs promotes the generation of anti-tumor immune responses and tumor rejection in murine model (144) . Combined with IL-12 therapy it enhanced the NKG2D pathway of NK cell activation and promoted NK cellmediated tumor suppression in mice (52). Enhanced antitumor effects could be also obtained using Treg elimination with administration of IFN-gamma (145) . Because proliferation and maintenace of CD4+CD25+ Tregs is IL-2 dependent, administration of anti-IL-2 antibodies together with IL-15 (which stimulates effector anti-tumor responses without stimulating Treg activity) enhanced anti-tumor immunity in mice (146) . Analogically in patients with colorectal cancer depletion of peripheral blood Tregs reversed tolerogenic state and increased effector T cell responses and IFN-gamma release directed against tumorassociated antigens (41) . Elimination of Treg cells, including lymph node resident Tregs, was also performed by the use of cyclophosphamide, anti-CD25 or anti-CTLA-4 antibodies, IL-2-toxin chimeric proteins or GITR ligands (38, 48, 68, 147) . Therefore the reasonable suggestion is that manipulation with the number of Tregs before vaccination with tumor-associated antigens could effectively augment anti-cancer immune response (39) . Another strategy consists in elimination of Tregs combined with genetic modification of tumor cells which makes them immunologically recognizable to effector T cells (147, 148) . Simultaneous removal of Th3/Tr1 regulatory cells may be another conceivable way to treat progressive tumors (123) . Experimental depletion of Tregs augmented also the response to DC-based immunotherapy (149) , which argues for the possibility that modification of TregDCs interactions depending on IDO and possibly HO-1 activity might improve the efficacy of anti-cancer treatment. Strategies to inhibit the IDO pathway might help to break tolerance to tumor tissues (150) . It was found that D-1-methyl-tryptophan isomer capable of blocking IDO activity is effective in abrogating the suppression of T cells created by IDO-expressing DCs isolated from tumordraining lymph nodes. Its potential clinical usefulness was confirmed in immunopotentiation of chemotherapy regimens using cyclophosphamide, paclitaxel or gemcitabine, when tested in mouse models of melanoma and breast cancer (151) . Similarly, using of zinc protoporphyrin IX, an HO-1 inhibitor, resulted in significant anti-tumor effects in mouse lung cancer (152) . Pharmacological activation of gammadelta T cells in vivo or adoptive cell therapy with in vitro expanded gammadelta T cells are considered as a novel immunotherapy in certain types of cancer (153, 154, 155, 156) . However, we do not know if combining these protocols with depletion of Tregs may improve outcome in cancer patients.
Regulatory T-cell-based immunotherapy of cancer meets many obstacles. Manipulation of Treg number could be unnecessary technique in some haematological malignancies, as it was shown that high T Foxp3+ cells were correlated with improved survival in B-cell derived Hodgkin's lymphomas (157) . Therefore, careful consideration should be taken before implementation of Treg-depletion therapy, and differences between haematological and epithelial cancers should be taken into regard (158) . Depletion of Tregs with use of anti-CD25 antibodies has short-time effects because unintentionally accelerates conversion of T CD4+CD25-cells into Tregs and might cause decrease of T cell effectors (159, 160) . Therapeutic use of synthetic oligonucleotides containing unmethylated CpG motifs (CpG-ODNs) which are known stimulators of innate and adaptive immunity could induce IDO up-regulation in DCs and promote pro-tumoral immune response (161, 162) . Similarly, immuno-vaccines containing prostaglandin E2 for sensitizing DCs to CCR7 ligands which direct their migration to the draining lymph nodes could unintentionally stimulate IDO expression on DCs (163).
PERSPECTIVES
According to the recently proposed hypothesis (79) , naturally occurring Tregs have evolved to modulate maternal response directed towards paternally-derived fetal alloantigens in placental vertebrates. Similarly to trophoblast possessing both maternal and paternal antigens, cancer is also a chimera consisting of cells presenting both self and changed through mutations antigens. Therefore, mechanisms engaging Tregs and their regulation might have important influence on the course of cancer growth and spreading in this group of animals, including humans. This is the reason why investigations performed on apparently distant fields like pregnancy and cancer could have close connections. Despite the fact that mechanisms of Treg regulation are still in progress, there is a hope for their broad use in the everyday clinical practice, and the first attempts of such management have already been described. However, much more information about interactions of Tregs with other cell populations is needed to provide safe treatment and reduction of potential sideeffects. The most probable directions of investigations will cover pathways of cytokine signaling between Tregs, DCs and trophoblast and cancer tissues, as well as molecules responsible for recruitment of Tregs into maternal-fetal interface and tumor sites. There are also strong suggestions that other immunocytes, like uNK, γδT cells or neutrophils have regulatory potential in certain conditions, and their connections with Tregs need to be precisely elucidated. The knowledge concerning intracellular pathways of signal transmission in Treg cells should be intensively studied in order to introduce methods of genetic manipulation of Tregs activity. In the future the methods of genomics will also bring the possibility of increase tumor immunogenicity. There is also burning need to learn how to obtain and expand Tregs having high activity directed against antigen-specified effectors. The failures of pregnancy, especially multiple failures after IVF-ET techniques, recurrent abortions and pre-eclampsia, have all great emotional burden for suffering patients and still wait for safe and effective therapeutic options, one of which could be manipulation with Tregs. 
